Dapagliflozin targets the sodium-coupled glucose transporter type 2 in the renal proximal tubule, preventing the reabsorption of glucose into the blood. It also has a direct effect on the islet alpha cell, which may counter its effect on glucose reabsorption in the kidney.
No takes yet. Share an insight, caveat, or question.
Hattersley et al. (2015) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: